A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide
Abstract Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.
Bibliographic Details
Main Authors: |
Keiko Yamaoka,
Shuichi Nagashima,
Nobukazu Okada,
Nagisa Sawayama,
Shinsuke Saito,
Manabu Takahashi,
Kenta Okada,
Kazuhiro Endo,
Masaru Koizumi,
Hideki Sasanuma,
Ken Ebihara,
Atsuko Kasajima,
Noriyoshi Fukushima,
Naohiro Sata,
Shun Ishibashi |
Format: | Article
|
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | Clinical Case Reports
|
Subjects: |
|
Online Access: | https://doi.org/10.1002/ccr3.4118
|